302440:KRXSK bioscience Co.,Ltd. Analysis

SK bioscience is trading at KRW 43,450, well above its 30‑day DCF fair value of ~KRW 29,485 and the computed SMA‑20 (46,680), SMA‑50 (48,220) and SMA‑200 (48,738), indicating an overextended price. The MACD is bearish (line below signal) and the RSI sits at 38.9, suggesting waning momentum, while the price is approaching the identified support at KRW 40,600 and still below the resistance of KRW 51,200. Volatility is elevated at roughly 50% over the past month and beta is modest at 0.59, but the stock has experienced a sharp drawdown of over 31% from recent highs. Fundamentals are weak: operating margin is –12.8%, free cash flow is negative (~KRW –254 bn), debt‑to‑equity is extremely high at 19.8, and earnings per share are essentially zero, leading to a forward PE of –61.9. Despite a robust revenue growth rate of 144% YoY, the company’s cash‑rich balance sheet (KRW 1,006 bn cash) is offset by sizable debt (KRW 411 bn) and ongoing R&D risk. The fear‑and‑greed index reads “Extreme Greed,” yet the underlying financial health and regulatory uncertainties in the biotech sector temper optimism. In short, the market price reflects speculative enthusiasm rather than intrinsic value, and the technical setup points to further downside pressure in the near term.